Article in Molecules (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.4field-weighted citation impact, top 20% of its field
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literature
Who cites it
5 citing papers in PubMed, 8 citations in OpenAlex.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
17 authors at 4 institutions in 2 countries.
Paulina BinieckaCentral Laboratory of Hematology, Department of Medical Laboratory and Pathology, Lausanne University Hospital and University of Lausanne, 1011 Lausanne, Switzerland.ORCID 0000-0003-0293-5793
Saki MatsumotoCentral Laboratory of Hematology, Department of Medical Laboratory and Pathology, Lausanne University Hospital and University of Lausanne, 1011 Lausanne, Switzerland.ORCID 0000-0002-3742-2384
Axel BelottiCentral Laboratory of Hematology, Department of Medical Laboratory and Pathology, Lausanne University Hospital and University of Lausanne, 1011 Lausanne, Switzerland.
Jessie JoussotLaboratory of Glycochemistry and Asymmetric Synthesis, Swiss Federal Institute of Technology (EPFL), 1015 Lausanne, Switzerland.
Jian Fei BaiLaboratory of Glycochemistry and Asymmetric Synthesis, Swiss Federal Institute of Technology (EPFL), 1015 Lausanne, Switzerland.ORCID 0000-0002-9128-5819
Somi Reddy MajjigapuLaboratory of Glycochemistry and Asymmetric Synthesis, Swiss Federal Institute of Technology (EPFL), 1015 Lausanne, Switzerland.ORCID 0000-0001-6422-5223
Paul ThoueilleService and Laboratory of Clinical Pharmacology, Department of Laboratory Medicine and Pathology, Lausanne University Hospital and University of Lausanne, 1011 Lausanne, Switzerland.ORCID 0000-0002-2305-4277
Dany SpaggiariService and Laboratory of Clinical Pharmacology, Department of Laboratory Medicine and Pathology, Lausanne University Hospital and University of Lausanne, 1011 Lausanne, Switzerland.
Vincent DesfontaineService and Laboratory of Clinical Pharmacology, Department of Laboratory Medicine and Pathology, Lausanne University Hospital and University of Lausanne, 1011 Lausanne, Switzerland.
Francesco PiacenteDepartment of Experimental Medicine, Section of Biochemistry, University of Genoa, 16132 Genoa, Italy.ORCID 0000-0001-5470-5987
Santina BruzzoneDepartment of Experimental Medicine, Section of Biochemistry, University of Genoa, 16132 Genoa, Italy.ORCID 0000-0003-2034-3716
Michele CeaDepartment of Internal Medicine and Medical Specialties, University of Genoa, 16132 Genoa, Italy.ORCID 0000-0002-1530-6729
Laurent A DecosterdService and Laboratory of Clinical Pharmacology, Department of Laboratory Medicine and Pathology, Lausanne University Hospital and University of Lausanne, 1011 Lausanne, Switzerland.
Pierre VogelLaboratory of Glycochemistry and Asymmetric Synthesis, Swiss Federal Institute of Technology (EPFL), 1015 Lausanne, Switzerland.ORCID 0000-0002-7399-2341
Alessio NencioniDepartment of Internal Medicine and Medical Specialties, University of Genoa, 16132 Genoa, Italy.
Michel A DuchosalCentral Laboratory of Hematology, Department of Medical Laboratory and Pathology, Lausanne University Hospital and University of Lausanne, 1011 Lausanne, Switzerland.
Aimable NahimanaCentral Laboratory of Hematology, Department of Medical Laboratory and Pathology, Lausanne University Hospital and University of Lausanne, 1011 Lausanne, Switzerland.ORCID 0000-0003-4968-3167
University of Lausanne · CHÉcole Polytechnique Fédérale de Lausanne · CHOspedale Policlinico San Martino · ITUniversity of Genoa · IT
Funding
European FP7 project INTEGRATA 813284-1Fondation Dr Dubois-Ferrière Dinu Lipatti no mumberFondation Emma Muschamp no numberSeventh Framework Program PANACREAS 256986
6 · The paper itself
Abstract
Targeting cancer cells that are highly dependent on the nicotinamide adenine dinucleotide (NAD+) metabolite is a promising therapeutic strategy. Nicotinamide phosphoribosyltransferase (NAMPT) is the rate-limiting enzyme catalyzing NAD
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Anticancer Activities of Novel Nicotinamide Phosphoribosyltransferase Inhibitors in Hematological Malignancies. · full record | OpenQuestion